QUELICIN (succinylcholine chloride) by Pfizer is blocker. Approved for mechanical ventilation. First approved in 1953.
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
QUELICIN (succinylcholine chloride) is a depolarizing neuromuscular blocking agent approved in 1953 for facilitating mechanical ventilation in acute care settings. It works by mimicking acetylcholine at the motor end plate, causing rapid depolarization and flaccid paralysis within one minute, lasting 4-6 minutes per dose. This drug is essential for rapid sequence intubation and short procedures requiring muscle relaxation.
As LOE approaches with moderate competitive pressure (30%), brand teams face declining opportunity and potential portfolio reductions unless line extensions prove defensible.
blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the…
Worked on QUELICIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on QUELICIN offers limited career advancement opportunity; roles are primarily operational, customer-relationship, or cost-management focused rather than innovation-driven. Career value lies in mastering hospital contracting, generic defense strategies, and portfolio rationalization in a declining therapeutic category.